Clinical trial

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

NCT07393425

Study summary

ClinicalTrials.gov

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Trastuzumab Deruxtecan Normalized identity: trastuzumab deruxtecan View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Taxane Chemotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Trastuzumab (or biosimilar) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Pyrotinib 320mg Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-02-02

PhasePHASE2

Conditions

HER2 + Breast Cancerunresolved

Interventions

Trastuzumab DeruxtecanDRUG · verified · RxNorm: trastuzumab deruxtecan

PertuzumabDRUG · verified · RxNorm: pertuzumab

Taxane ChemotherapyDRUG

Trastuzumab (or biosimilar)DRUG

Pyrotinib 320mgDRUG

Sponsors & collaborators

Shanghai Jiao Tong University School of Medicinelead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07393425 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.